Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Ocrelizumab (Ocrevus) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults; it is also indicated for primary progressive MS in adults.
• A total of 9 studies from systematic reviews and meta-analyses were reviewed to gather information about ocrelizumab's safety and effectiveness compared to other drugs used for MS.
• In terms of efficacy, ocrelizumab was found superior or comparable to mitoxantrone, siponimod, natalizumab, and rituximab, among others, in delaying disease progression. It performed best on the Timed 25-Foot Walk test but had low certainty. For RMS patients specifically, it ranked highly alongside alemtuzumab and natalizumab regarding disability progression reduction.
• Safety profiles indicate that ocrelizumab has fewer serious adverse events compared to placebo when treating PMS. However, there were higher overall adverse event rates noted, particularly infusion-related reactions and infections, especially within PPMS populations as per Cochrane review findings.
• The drug showed decreasing IgG levels over time, which could be associated with increased infection risks according to studies focusing on immunoglobulin changes during treatment periods primarily involving RMS patients.
• According to ABN guidelines classification based on analysis conducted within UK standards, ocrelizumab was contextually placed under moderate-to-high efficacy categories concerning relapse rate reductions, highlighting its significant role among newer therapies available today.